ClinicalTrials.gg
RecruitingNCT06325852Updated Nov 4, 2024

Directional Bilateral Thalamic Patterned Stimulation (Chronos)

An interventional study of DBS programing in Essential Tremor, sponsored by Alfonso Fasano. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by Alfonso Fasano · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Essential Tremor with a site in Canada — 8 open to participants now, 11 under way, 1 of them phase 3. Essential Tremor · Canada.

Planned enrollment
14th of 22
15 · median 22
Started
2024
the only one that year
No phase
12 of 26
4 open now
Primary completion
2026-04
later than 3 of 10 live
Registered
22nd of 26
by date
Lead sponsor
1 of 26
Alfonso Fasano

Among the 26 studies in Essential Tremor with a site in Canada, this one is the 14th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2024, is one of 12 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 22nd registered.

Essential Tremor

272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.

Browse Essential Tremor studies →

Open to participants now

8 of the 26 studies in Essential Tremor with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Essential Tremor with a site in Canada, or all of them as a file.
02

Study summary

Population Size and Eligible Patients: The investigators aim to recruit 5 to 10 patients with tremors who have previously undergone Ventral Intermedius Deep Brain Stimulation (VIM-DBS) treatment but have experienced early or late loss of benefits. Additionally, the investigators will enroll ten patients with essential tremor who require VIM-DBS surgery. These individuals will undergo bilateral implantation of Boston Scientific Genus Implantable Pulse Generator (IPG) devices, connected to Boston Scientific Cartesia™ 8-contact Directional Leads.

Study Design: This study comprises two distinct phases. Phase 1 is a cross-sectional investigation designed to identify the optimal algorithm for patterned stimulation in the VIM region . Phase 2 is a prospective clinical trial focusing on the assessment of safety and efficacy of bilateral VIM-DBS in patients with essential tremor.

Objectives: The primary objective in Phase 2 is to evaluate the safety and effectiveness of bilateral VIM-DBS in individuals with essential tremor. In Phase 1, the investigators seek to explore the impact of the Chronos programming software on tremor patients who have experienced early or late loss of benefits.

03

Conditions studied

  • Essential Tremor

Browse trials for

Keywords

  • Deep Brain Stimulation
  • Chronos Physician Programmer
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Phase 1: 5 to 10 tremor patients already treated with VIM-DBS but not doing well due to early and/or late loss of benefits (i.e. tremor scores ON stimulation identical or greater than before surgery in absence of stimulation).
  2. Phase 2: 10 Essential Tremor patients in need of DBS surgery.
  3. Written and signed .
  4. Age 18 to 85 years old.
  5. Subject must have Essential Tremor, as defined by all the following criteria: (a) isolated tremor syndrome consisting of bilateral action tremor; (b) at least three years duration; and (c) with or without tremor in other locations (e.g., head, voice, or low limbs) [1].
  6. Soft signs (categorizing patients as Essential Tremor-plus) will be allowed and noted in the patient's chart.
  7. Subject must be on stable dose of anti-tremor medication for at least 4 weeks prior to screening.
  8. Subject had no botulinum injection for at least three months prior to screening.
  9. Subject does not have a significant other medical condition biasing the study finding in investigator's opinion.

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or inability to follow the procedures specified by the protocol.
  2. Presence of significant psychiatric or cognitive condition likely to compromise the subject's ability to comply with requirements of the study protocol.
  3. Untreated depression.
  4. Any current drug or alcohol abuse, as determined by the investigator.
  5. History of suicidal attempt within the last 1 year prior to consent or current active suicidal ideation as determined by the investigator.
  6. Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints.
  7. Any terminal illness with of \< 12 months.
  8. Participation in any other interventional clinical trial (e.g. drug, device).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Phase 1

    5 to 10 patients with tremor already treated with VIM-DBS but not doing well because of early or late loss of benefits will be recruited by the PI over a 6 months period. If interested, the potential participants will be screened, informed, and consented by a research coordinator. Before the replacement of their IPG (implantable pulse generator), a baseline measurement will be performed.

    Other: DBS programing

  • Experimental
    Phase 2

    Ten patients with ET needing DBS-VIM surgery will be recruited and will receive Boston Scientific Genus IPG bilaterally connected to Boston Scientific Cartesia™ 8-contact Directional Leads. The programming will be done in four different settings/periods during the course of 8 months.

    Other: DBS programing

Interventions

  • OtherDBS programing

    The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.

06

What researchers measure

Primary outcomes

  1. Tremor Rating Scale (Part A-B)

    Range from 0-46. with 0 representing no tremor and 46 representing severe tremor.

    Time frame: Phase 1-Baseline

  2. Tremor analysis

    Using accelerometers

    Time frame: Phase 1-Baseline

  3. Tremor Rating Scale (A-C)

    Range from 0-46. with 0 representing no tremor and 46 representing severe tremor.

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  4. Tremor analysis (meter per second squared)

    Using accelerometers

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  5. Gait speed (meter per second)

    Gait Analysis

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  6. Base of support (meter)

    Gait Analysis

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  7. Step length (meter)

    Gait Analysis

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  8. Stride length (meter)

    Gait Analysis

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  9. Single stance time and double stance time (seconds)

    Gait Analysis

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  10. Tandem gait

    Gait Analysis

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  11. Posturography (newtons)

    Using Proteokinetics Zeno System

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  12. Quality of life in Essential Tremor Questionnaire (QUEST)

    Range from 0-40, with 0 representing no tremor and 40 representing severe tremor.

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

  13. Speech analysis

    automated analysis pipeline in MatLab

    Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2026, 20 months after the start.

Of 77 non-industry interventional studies with no phase under Essential Tremor, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26. This study's planned 20 months is below that.

Counting every sponsor, half of 95 studies reached it within 45 months; a quarter within 19 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 22, 2024
StartActual
Jul 16, 2024
Primary completionEst.
Apr 1, 2026
CompletionEst.
Jan 1, 2027
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06325852
Lead sponsor
Alfonso Fasano
Responsible party
Alfonso Fasano (MD, PhD, FAAN, Professor, University of Toronto) — Sponsor-investigator
First posted
Mar 22, 2024
Start date
Jul 16, 2024
Primary completion
Apr 1, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 4, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion